FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896793945> ?p ?o ?g. }

• W2896793945 endingPage "e232" @default.
• W2896793945 startingPage "e231" @default.
• W2896793945 abstract "Radiation therapy can be ototoxic and dose constraints to the cochlea – mean <45Gy will give ∼<30% sensory-neural hearing loss. Cis is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Little is known about the incidence of hearing loss when using different cisplatin regimens in patients receiving concomitant CRT with modern day radiation therapy techniques. Therefore, we assessed prospectively the incidence of ototoxicity in patients receiving weekly or tri-weekly Cis concomitantly with volumetric modulated arc radiotherapy (VMAT). HNSCC patients receiving definitive or adjuvant cis-based CRT were included. Cis was administered weekly (40 mg/m2 weekly, total 7 cycles) or tri-weekly (100 mg/m2 every three weeks, total 3 cycles). Radiation was administered to a total dose of 70 Gy for definitive treatment or 66 Gy for adjuvant treatment (2 Gy/fraction). Intensity-modulated radiation therapy was used in all cases. Pure-tone air-conduction audiometry was performed in all patients before and after completion of CRT. The primary endpoint of the analysis was Common Terminology Criteria for Adverse Event (CTCAE v4.0) hearing change ≥3 at the completion of CRT. The cochlea was contoured by one dosimetrist and assessed by two physicians for accuracy. A total of 96 patients (M:77/F:19) were included (56 oropharynx patients and 40 non-oropharynx HNSCC)). The median age was 55 years (range 26-78) 68 patients received weekly cis and 28 received the tri-weekly regimen. 58 patients received definitive treatment and 38 adjuvant treatment. Nine patients (13%) receiving weekly cis experienced G3 ototoxicity vs 14 patients (50%) who received tri-weekly cis (p<0.001, OR=6.4, 95% CI= 2.1-20.7). Risk of ototoxicity was not associated with age, cis cumulative dose, sex, tumor primary site, or CRT modality (definitive vs. adjuvant). After adjusting for these factors in a multivariable model cis schedule remained significant (OR=8.7, 95% CI 2.31-32.75, p=0.001). With a minimum follow-up of three months, the complete response rate after treatment was 84% for weekly CRT and 86% for tri-weekly CRT (p=NS). Cochlear mean dose of 13.76 Gy +/- 8.5 Gy to bilateral cochlea was achieved. With mean cochlear doses of ≤ 22Gy bilaterally, tri-weekly Cis-based CRT increased the risk of grade 3 irreversible severe ototoxicity compared to weekly Cis. This risk of ototoxicity should be discussed with patients that are candidates for cis-based CRT." @default.
• W2896793945 created "2018-10-26" @default.
• W2896793945 creator A5000278206 @default.
• W2896793945 creator A5009574782 @default.
• W2896793945 creator A5013219528 @default.
• W2896793945 creator A5017123314 @default.
• W2896793945 creator A5020139652 @default.
• W2896793945 creator A5030652856 @default.
• W2896793945 creator A5032012412 @default.
• W2896793945 creator A5036694238 @default.
• W2896793945 creator A5039263552 @default.
• W2896793945 creator A5054721345 @default.
• W2896793945 creator A5066127518 @default.
• W2896793945 creator A5067727347 @default.
• W2896793945 creator A5070837806 @default.
• W2896793945 creator A5073117866 @default.
• W2896793945 creator A5075285911 @default.
• W2896793945 creator A5077168338 @default.
• W2896793945 date "2018-11-01" @default.
• W2896793945 modified "2023-09-27" @default.
• W2896793945 title "A Prospective Analysis of Ototoxicity in Modern Radiation Therapy Treatments for Head and Neck Squamous Cell Carcinoma (HNSCC) Patients Receiving Concomitant Chemo-Radiation (CRT) with Weekly or Tri-weekly Cisplatin (Cis)" @default.
• W2896793945 doi "https://doi.org/10.1016/j.ijrobp.2018.07.786" @default.
• W2896793945 hasPublicationYear "2018" @default.
• W2896793945 type Work @default.
• W2896793945 sameAs 2896793945 @default.
• W2896793945 citedByCount "0" @default.
• W2896793945 crossrefType "journal-article" @default.
• W2896793945 hasAuthorship W2896793945A5000278206 @default.
• W2896793945 hasAuthorship W2896793945A5009574782 @default.
• W2896793945 hasAuthorship W2896793945A5013219528 @default.
• W2896793945 hasAuthorship W2896793945A5017123314 @default.
• W2896793945 hasAuthorship W2896793945A5020139652 @default.
• W2896793945 hasAuthorship W2896793945A5030652856 @default.
• W2896793945 hasAuthorship W2896793945A5032012412 @default.
• W2896793945 hasAuthorship W2896793945A5036694238 @default.
• W2896793945 hasAuthorship W2896793945A5039263552 @default.
• W2896793945 hasAuthorship W2896793945A5054721345 @default.
• W2896793945 hasAuthorship W2896793945A5066127518 @default.
• W2896793945 hasAuthorship W2896793945A5067727347 @default.
• W2896793945 hasAuthorship W2896793945A5070837806 @default.
• W2896793945 hasAuthorship W2896793945A5073117866 @default.
• W2896793945 hasAuthorship W2896793945A5075285911 @default.
• W2896793945 hasAuthorship W2896793945A5077168338 @default.
• W2896793945 hasConcept C126322002 @default.
• W2896793945 hasConcept C141071460 @default.
• W2896793945 hasConcept C197934379 @default.
• W2896793945 hasConcept C2776694085 @default.
• W2896793945 hasConcept C2777793932 @default.
• W2896793945 hasConcept C2778239845 @default.
• W2896793945 hasConcept C2778496288 @default.
• W2896793945 hasConcept C2778534666 @default.
• W2896793945 hasConcept C2779384505 @default.
• W2896793945 hasConcept C2780493683 @default.
• W2896793945 hasConcept C2781413609 @default.
• W2896793945 hasConcept C509974204 @default.
• W2896793945 hasConcept C548259974 @default.
• W2896793945 hasConcept C71924100 @default.
• W2896793945 hasConceptScore W2896793945C126322002 @default.
• W2896793945 hasConceptScore W2896793945C141071460 @default.
• W2896793945 hasConceptScore W2896793945C197934379 @default.
• W2896793945 hasConceptScore W2896793945C2776694085 @default.
• W2896793945 hasConceptScore W2896793945C2777793932 @default.
• W2896793945 hasConceptScore W2896793945C2778239845 @default.
• W2896793945 hasConceptScore W2896793945C2778496288 @default.
• W2896793945 hasConceptScore W2896793945C2778534666 @default.
• W2896793945 hasConceptScore W2896793945C2779384505 @default.
• W2896793945 hasConceptScore W2896793945C2780493683 @default.
• W2896793945 hasConceptScore W2896793945C2781413609 @default.
• W2896793945 hasConceptScore W2896793945C509974204 @default.
• W2896793945 hasConceptScore W2896793945C548259974 @default.
• W2896793945 hasConceptScore W2896793945C71924100 @default.
• W2896793945 hasIssue "3" @default.
• W2896793945 hasLocation W28967939451 @default.
• W2896793945 hasOpenAccess W2896793945 @default.
• W2896793945 hasPrimaryLocation W28967939451 @default.
• W2896793945 hasRelatedWork W1978232913 @default.
• W2896793945 hasRelatedWork W1979599244 @default.
• W2896793945 hasRelatedWork W2064900812 @default.
• W2896793945 hasRelatedWork W2110043256 @default.
• W2896793945 hasRelatedWork W2139331000 @default.
• W2896793945 hasRelatedWork W2336726368 @default.
• W2896793945 hasRelatedWork W2999983825 @default.
• W2896793945 hasRelatedWork W3114931392 @default.
• W2896793945 hasRelatedWork W4229488205 @default.
• W2896793945 hasRelatedWork W4287964903 @default.
• W2896793945 hasVolume "102" @default.
• W2896793945 isParatext "false" @default.
• W2896793945 isRetracted "false" @default.
• W2896793945 magId "2896793945" @default.
• W2896793945 workType "article" @default.